Healthcare

This research service summarizes the technology breakthroughs in spinal implants with respect to biomaterial technologies such as metals; polymers; ceramics; combination products and stem cells. There is also a focus on industry trends and novel biomaterial technology offerings that are enabling the advancement of new and improved spinal implants. ...

A growing trend towards miniaturizing laboratory practices has been a major driving force behind the steady increase of innovations in the space of Lab on a chip. With the advent of novel microfluidics solutions and cost effective materials for chip development, a myriad of devices for clinical and research utilization can be seen. This research re...

Integrated healthcare (IHC) is the design, management and delivery of healthcare services along the continuum of care. IHC is a growing trend is fast encompassing diagnosis, treatment, long-term care, rehabilitation services and predictive modelling for coordinated care and population health management. The key driving forces behind IHC are: increa...

The total market, as defined by this study, includes next-generation sequencing instruments and reagents. Instruments include those that use newer technology than traditional capillary electrophoresis (CE) sequencing, such as sequencing-by-synthesis, sequencing-by-ligation, single-molecule sequencing, and semiconductor sequencing. This research ser...

This research service focuses on antiviral/antiretroviral therapeutics for the treatment of HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinica...

This issue of Vital Signs, released on June 2, 2014, discusses the latest strategy surrounding mega deals in the pharma/biotech industry, Eurofins agreement to acquire ViroCor-IBT Laboratories, Qiagens acquisition of BIOBASE, and the FDAs latest announcement on regulatory requirements for biosimilars.

This issue of Vital Signs, released on May 1, 2014, discusses the mega deals brewing in the pharma/biotech industry, Pfizer Incs Xalkori for non-small cell lung cancer, Novartis halt on RNAi development efforts, the high-ranked Malaysian healthcare system, Roches acquisition of IQuums Liat Analyzer, and Bio-Rads acquisition of GnuBio.

This issue profiles digital radiography systems to increase imaging efficiency at reduced radiation dosage, diagnostic imaging app for all imaging modalities, medical grade X-ray detector from plastic.

In 2013, healthcare moved towards access, transparency,  investments, and spending. In 2014, Frost & Sullivan anticipates new launches to occur across the life sciences spectrum, from preventive medicine to treating complex diseases. This market insight touches upon major events that occurred in 2013 and how 2014 is expected to shape up, includi...